Development and performance characteristics of Platelet Virtual Crossmatch (PLT VXM), a software application for the evaluation and management of platelet transfusion–refractory patients

Platelet (PLT) transfusion refractoriness increases bleeding complications, hospital stays, and PLT inventory usage. Immune‐mediated refractoriness can be evaluated for using a physical PLT crossmatch with ABO‐compatible inventory and, if positive, managed with HLA‐compatible PLT inventory and donors. Manual completion of these complex tasks can be time‐consuming and potentially error‐prone. This study was conducted to determine if a Web‐based software application could improve process efficiency and accuracy.

[1]  G. Edgren,et al.  HLA‐selected platelets for platelet refractory patients with HLA antibodies: a single‐center experience , 2018, Transfusion.

[2]  Liang-In Lin,et al.  Epitope‐based matching for HLA‐alloimmunized platelet refractoriness in patients with hematologic diseases , 2010, Transfusion.

[3]  J. Eikenboom,et al.  The clinical impact of platelet refractoriness: correlation with bleeding and survival , 2008, Transfusion.

[4]  T. Lister,et al.  Relative Importance of Immune and Non‐Immune Causes of Platelet Refractoriness , 1994, Vox sanguinis.

[5]  J. Gornbein,et al.  Selecting donors of platelets for refractory patientson the basis of HLA antibody specificity , 2000, Transfusion.

[6]  Edward J. Lee,et al.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. , 2005, Blood.

[7]  W. Hiddemann,et al.  Frequency and causes of refractoriness in multiply transfused patients , 1997, Annals of Hematology.

[8]  J. Lunz,et al.  EDTA Treatment of Serum Unmasks Complement-Mediated Prozone Inhibition in Human Leukocyte Antigen Antibody Testing. , 2016, American journal of clinical pathology.

[9]  K. Schulman,et al.  Platelet transfusions: Utilization and associated costs in a tertiary care hospital , 2000, American journal of hematology.

[10]  F. Grumet,et al.  Platelet transfusion therapy; the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. , 1969, The New England journal of medicine.

[11]  J. Rowe,et al.  Selection of platelets for refractory patients by HLA matching and prospective crossmatching , 1992, Transfusion.

[12]  F. Marincola,et al.  HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. , 2006, Blood.

[13]  A. Nambiar,et al.  Longitudinal management with crossmatch‐compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME) , 2012, Transfusion.

[14]  P. Kopko,et al.  Methods for the selection of platelet products for alloimmune‐refractory patients , 2015, Transfusion.

[15]  F. Plapp,et al.  Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. , 1988, American journal of clinical pathology.

[16]  T. Gniadek,et al.  The effect of serum pretreatment regimens for the detection of HLA class I antibodies in platelet‐refractory patients , 2020, Transfusion.

[17]  P. Rebulla,et al.  Utility of cross‐matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review , 2014, Transfusion.

[18]  E. Hod,et al.  Platelet Transfusion Refractoriness , 2024, Plasmatology.

[19]  M. Gandhi,et al.  How do I … manage the platelet transfusion–refractory patient? , 2017, Transfusion.